AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)
AAPL 203.88 +0.14 (+0.07%)MSFT 123.45 +0.4 (+0.33%)FB 178.27 +0.03 (+0.02%)ZNGA 5.44 +0.09 (+1.59%)NVDA 186.25 +0.19 (+0.10%)WBA 54.62 -0.33 (-0.60%)GOOG 1237.48 -0.16 (-0.01%)PIH 5.25 -0.05 (-0.94%)

Balance Sheet APLS Quote Apellis Pha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 25 176 176
ShortTermInvest 0 0 0
Cash 25 176 176
AccountReceivab 0 0 0
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 3 1 2
TotalCurrentAss 27 182 202
PPE 0 0 0
AccumulatedDepr 0 0 0
NetPPE 0 0 0
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 1
TotalNonCurrent 0 0 1
TotalAssets 27 182 204
ShortTermDebt 0 0 2
AccountsPayable 3 4 10
TaxesPayable 0 0 0
AccruedLiabilit 1 3 5
DeferredRevenue 0 0 0
OtherCurrentLia 0 0 0
TotalCurrentLia 4 7 17
Debt 0 26 25
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 0 0 0
TotalNonCurrent 0 27 26
TotalLiabilitie 4 33 43
CommonStock 0 0 0
AdditionalPaidI 30 298 438
RetainedEarning -98 -149 -277
AccumulatedOthe 0 0 0
TotalStockholde 24 149 161
TotalLiabilitie 27 182 204
Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.